Abstract
Alzheimers disease has become one of the most serious healthcare problems nowadays, where age is clearly the major risk factor. The pathology of the disease is characterized by the formation of senile plaques outside the neurons, which are composed, predominantly, by the β-amyloid (Aβ) peptide. Considering that β-secretase is an aspartyl protease involved in the cleavage of the amyloid precursor, the first step required for the formation of Aβ, becomes an attractive therapeutic target for drug design. A virtual screening approach based on flexible docking was applied in order to identify potential inhibitor candidates of β-secretase, since the docking method used here showed to be able to reproduce the binding modes of crystallographic complexes. After validation, ten potential inhibitors were selected and evaluated with respect to the analysis of toxicological groups. The most promising inhibitor candidate was analyzed in a molecular dynamics trajectory to reinforce, theoretically, the potential inhibitory activity. Overall results obtained here suggest that this novel potential β-secretase inhibitor could be a promising pharmaceutical for the Alzheimers disease treatment.
Current Bioactive Compounds
Title: In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease
Volume: 5 Issue: 2
Author(s): Vinicius Barreto da Silva, Adriana Mieco Namba, Daniela Godoy Pantalena, Taina Ferreira do Prado and Carlos Henrique Tomich de Paula da Silva
Affiliation:
Abstract: Alzheimers disease has become one of the most serious healthcare problems nowadays, where age is clearly the major risk factor. The pathology of the disease is characterized by the formation of senile plaques outside the neurons, which are composed, predominantly, by the β-amyloid (Aβ) peptide. Considering that β-secretase is an aspartyl protease involved in the cleavage of the amyloid precursor, the first step required for the formation of Aβ, becomes an attractive therapeutic target for drug design. A virtual screening approach based on flexible docking was applied in order to identify potential inhibitor candidates of β-secretase, since the docking method used here showed to be able to reproduce the binding modes of crystallographic complexes. After validation, ten potential inhibitors were selected and evaluated with respect to the analysis of toxicological groups. The most promising inhibitor candidate was analyzed in a molecular dynamics trajectory to reinforce, theoretically, the potential inhibitory activity. Overall results obtained here suggest that this novel potential β-secretase inhibitor could be a promising pharmaceutical for the Alzheimers disease treatment.
Export Options
About this article
Cite this article as:
da Silva Barreto Vinicius, Namba Mieco Adriana, Pantalena Godoy Daniela, do Prado Ferreira Taina and de Paula da Silva Tomich Carlos Henrique, In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788452000
DOI https://dx.doi.org/10.2174/157340709788452000 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Current Alzheimer Research An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
Current Medicinal Chemistry Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews The Key Role of Membranes in Amyloid Formation from a Biophysical Perspective
Current Protein & Peptide Science Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia
Current Alzheimer Research Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Adaptive Behavior in Williams-Beuren Syndrome, Down Syndrome, and Autism Spectrum Disorder
Current Psychiatry Reviews The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research
Current Alzheimer Research Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Can Acetylcholinesterase Serve as a Target for Developing More Selective Insecticides?
Current Drug Targets Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering
Current Pharmaceutical Biotechnology